Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
October 07 2022 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2022
Commission File Number: 001-40858
XORTX THERAPEUTICS INC.
(Translation of registrant’s name into
English)
3710 – 33rd Street NW
Calgary, Alberta, Canada T2L 2M1
(Address of
principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
XORTX Therapeutics Inc. |
|
(Registrant) |
|
|
|
|
|
Date: October 7, 2022 |
By: |
/s/ Allen Davidoff |
|
|
Name: |
Allen Davidoff |
|
|
Title: |
President and Chief Executive Officer |
Form 6-K Exhibit Index
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024